Phaseline

Targets › INSULIN

INSULIN: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.

Open in Phaseline: the race on INSULIN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterAllogenic Human Islet Cells
Intraportal infusion of insulin-producing pancreatic islet cells for metabolic restoration
INSULIN, GCGRPhase 2Type 1 Diabetes Mellitus; Diabetes Mellitus, Type 1Aug 2027

Conditions

Type 1 Diabetes Mellitus (1) Diabetes Mellitus, Type 1 (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

GCGR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.